Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alvelestat in Bronchiolitis Obliterans Syndrome After Stem Cell Transplant
NCT02669251Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2016
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of alvelestat in Bronchiolitis Obliterans Syndrome (BOS) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Optimal Biologic Dose at 8 weeks, Clinical Efficacy based on FEV1 at 6 months and 1 more. Started Apr 2016; status: active, not recruiting.
02
Drugs
alvelestat
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on NCT02669251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02669251.